Original article

Early gastric cancer shows different associations with adipose tissue volume depending on histological type

KENSUKE OTANI¹, JOJI KITAYAMA¹, SHOICHI KAISAKI¹, HIRONORI ISHIGAMI¹, AKIO HIDEMURA¹, MITSUHIRO FUJISHIRO², MASAO OMATA², and HIROKAZU NAGAWA¹

¹Department of Surgical Oncology, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan

²Department of Gastroenterology, The University of Tokyo, Tokyo, Japan

Abstract

Background. Visceral obesity is known to be a risk factor for diabetes and cardiovascular disease. Cancer of the gastric cardia has been shown to have a close association with obesity in Western countries. In order to examine the possible relationship between fat volume and the development of gastric cancer (GC), we quantified visceral and subcutaneous fat areas of computed tomography (CT) images of patients with early GC.

Methods. A total of 210 patients who underwent endoscopic resection or surgical gastrectomy and whose disease was pathologically diagnosed as early GC were investigated for total fat area (TFA), visceral fat area (VFA), and subcutaneous fat area (SFA) with Fat Scan software, using a CT slice at the umbilical level, and the relationships of these findings with clinical and pathological data were analyzed. The same analysis was performed in 147 patients with early colorectal cancer (CRC).

Results. TFA, VFA, and SFA values in GC patients were not significantly different from the values in CRC patients. These values did not differ with the location of the GC. However, patients with undifferentiated-type GC had significantly smaller VFAs and SFAs than those with differentiated-type GC. Among the patients with undifferentiated GC, TFA and SFA values in the patients with submucosal cancer were significantly smaller than those in the patients with mucosal cancer.

Conclusion. GC has different associations with adipose tissue volume according to its histological type. As compared with differentiated GC, lower adipose tissue volume may be a preferential environment for the development and progression of undifferentiated GC.

Key words Early gastric cancer · Visceral fat · Subcutaneous fat · Differentiated type · Undifferentiated type

Introduction

The metabolic syndrome is one of the greatest concerns in healthcare in Japan, as well as in Western countries. Abdominal obesity has been shown to be associated with an increased risk not only for cardiovascular disease [1–7], diabetes [8], and hypertension [9] but also for malignant disease [10–14]. Since Lew and Garfinkel [15] first reported that overweight status and obesity increased the risk of mortality from cancer, many epidemiologic studies have shown a positive association between obesity and cancers in various organs, such as the endometrium [16], kidney [17], breast (in postmenopausal women) [18], colon [19], gallbladder [20], prostate [21], thyroid [22, 23], gastric cardia [24–26], and esophagus [27].

The incidence of gastric cardia cancer has been increasing in Western countries, whereas the rate of distal stomach cancer has declined [28–33]. This divergent trend in incidence suggests different etiologies of these gastric cancers (GCs). Obesity was associated with gastric cardia cancer in some case-control studies in Western countries [34, 35], but its association with distal stomach cancer has not been well examined [36]. Chow et al. [24] performed a multicenter population-based case-control study in the United States in 1998, and reported that being in the highest quartile of body mass index (BMI) compared with being in the lowest quartile was associated with an increased risk of esophageal adenocarcinoma and gastric cardia carcinoma. Lagergren et al. [27] reported similar results from a large study of the Swedish population. On the other hand, in 2003, Zhang et al. [37] reported that the BMI of patients with gastric cardia cancer was significantly lower than that of patients with noncardia GC, indicating that being underweight was positively associated with gastric cardia carcinoma. Thus, the association between obesity and gastric cardia cancer remains controversial. Kubo and Corley [38] performed a system-

atic review and metaanalysis of 14 studies and concluded that a high BMI was weakly associated with the risk of cancer in the gastric cardia.

Obesity is manifested as a markedly high volume of adipose tissue. Recent studies have demonstrated that adipocytes produce a variety of secretory peptides, named adipokines [39, 40]. More recently, some adipokines, such as leptin and adiponectin, have been shown to critically regulate the biological behavior of malignant cells [41–50], raising the possibility that adipocytes may have positive roles in the development of malignant diseases through the secretion of adipokines in an endocrine or intracrine manner. In addition, it has been suggested that the biochemical characteristics of visceral and subcutaneous adipose tissues are somewhat different [51, 52].

Taking these findings into account, we raised the hypothesis that the distribution as well as the volume of adipose tissue may have a specific association with human cancer. However, there are no reports describing adipose tissue volume or distribution in cancer patients. In this study, therefore, we measured visceral and subcutaneous fat areas separately on CT images of patients with early GC, and investigated the relationship of these findings with various clinical and pathological parameters of GC.

Patients, materials, and methods

Patients and methods

In this study, we examined the volume of visceral and subcutaneous fat in one slice of a CT scan, using Fat Scan software (N2 System, Osaka, Japan). Several studies have revealed that the visceral fat area (VFA) shown from a single scan obtained at the level of the umbilicus (the level from L4 to L5) is highly correlated with the total visceral fat volume [53–55]. Hence, we used a slice of a CT image at the umbilical level to measure VFAs and subcutaneous fat areas (SFAs). We collected the data for SFA and VFA by a previously reported technique [55, 56]. We determined the total fat area (TFA) as the sum of the SFA and VFA, and the V/S ratio, as the VFA divided by the SFA.

We retrospectively studied 550 patients whose disease was pathologically diagnosed as early GC who underwent surgical gastrectomy or endoscopic resection between April 2001 and February 2007 at the Tokyo University Hospital. Early GC, according to the classification established by the Japanese Research Society for Gastric Cancer, is defined as a lesion confined to the mucosal or submucosal layer. We selected only patients with early GC, because advanced-stage cancer may affect the volume of adipose tissue through causing

diminished appetite and altered metabolism. Therefore, we also excluded patients with any other malignant diseases.

Among the 550 patients, a CT scan image of the umbilical slice was unavailable in 332 patients, who were excluded from this study. Three patients had had a previous gastrectomy and 5 patients had other advanced malignant diseases; these 8 patients were also excluded, because gastrectomy or the presence of other malignancies may affect the fat area. Finally, 210 patients (174 men and 36 women) for whom a CT image of a slice at the umbilical level was available were enrolled in this study. We also examined, in a similar manner, 147 patients (102 men and 45 women) with early colorectal cancer (CRC) as a control group in this study.

In order to analyze the associations of SFA and VFA with various parameters in cardia cancer, we used the criteria for cardia cancer proposed by Siewert and Stein [57]. According to their criteria, adenocarcinomas whose center lay within 1 cm proximal to and 2 cm distal from the gastroesophageal junction (Siewert type II) were classified as cardia cancer, and other adenocarcinomas were categorized as noncardia cancer.

This study was approved by the ethics committee of the University of Tokyo.

Statistical analysis

We performed statistical analyses of TFA, VFA, SFA, and the V/S ratio, as well as blood count data, blood chemical data, and pathological data. Spearman rank correlations were calculated to determine the relationship between nominal data and continuous data, and Mann-Whitney's *U*-test was used to determine the correlation between two kinds of continuous data. Values of $P < 0.05$ were considered to be significant.

Results

Total fat area (TFA), visceral fat area (VFA), and subcutaneous fat area (SFA) in gastric and colorectal cancers

The data for our entire patient cohort are shown in Table 1. BMI and TFA values showed no significant difference between patients with GC and those with CRC. Both BMI and TFA were the same in male and female patients. In contrast, in both GC and CRC patients, VFA was significantly larger in male patients, while SFA was larger in female patients (GC, $P < 0.001$; CRC, $P < 0.01$). This is consistent with the data of the general population without cancer [58]. However, when VFA and SFA were separately compared in each sex, both parameters mostly showed the same values. Inter-

Table 1. BMI and fat areas in patients with early gastric and colorectal cancers

Male (<i>n</i> = 276)			
	Gastric cancer (<i>n</i> = 174)	Colorectal cancer (<i>n</i> = 102)	<i>P</i> value
BMI (kg/m ²)	22.8 ± 2.9	22.9 ± 3.1	0.979
TFA (cm ²)	199.6 ± 89.2	185.2 ± 85.4	0.175
VFA (cm ²)	101.2 ± 52.7	91.9 ± 51.9	0.144
SFA (cm ²)	98.4 ± 45.0	93.2 ± 43.9	0.240
V/S	1.07 ± 0.41	1.05 ± 0.53	0.434
Female (<i>n</i> = 81)			
	Gastric cancer (<i>n</i> = 36)	Colorectal cancer (<i>n</i> = 45)	<i>P</i> value
BMI (kg/m ²)	21.9 ± 3.3	21.4 ± 3.2	0.372
TFA (cm ²)	208.7 ± 93.2	175.6 ± 82.6	0.081
VFA (cm ²)	56.6 ± 36.8	50.2 ± 29.5	0.608
SFA (cm ²)	152.1 ± 64.6	125.4 ± 60.2	0.037*
V/S	0.43 ± 0.34	0.47 ± 0.42	0.464

*P < 0.05

Data values are means ± SD

BMI, body mass index; TFA, total fat area; VFA, visceral fat area; SFA, subcutaneous fat area; V/S, VFA/SFA; GC, gastric cancer; CRC, colorectal cancer

Table 2. Fat areas in patients with cardia and noncardia cancers

Male			
	Cardia (<i>n</i> = 11)	Noncardia (<i>n</i> = 161)	<i>P</i> value
TFA (cm ²)	191.5 ± 60.8	201.0 ± 91.0	0.781
VFA (cm ²)	99.6 ± 37.9	101.8 ± 53.7	0.963
SFA (cm ²)	91.9 ± 29.9	99.1 ± 46.0	0.781
Female			
	Cardia (<i>n</i> = 2)	Noncardia (<i>n</i> = 33)	<i>P</i> value
TFA (cm ²)	307.0 ± 136.1	207.9 ± 86.1	0.256
VFA (cm ²)	88.5 ± 85.8	56.0 ± 33.5	0.670
SFA (cm ²)	218.5 ± 50.3	151.8 ± 61.0	0.136

Data values are means ± SD

Cancer locations were unclear in 2 male patients and 1 female patient; these patients were excluded from this analysis

estingly, both parameters tended to be higher in patients with GC as compared with those with CRC, although the differences were not statistically significant, except for SFA in female patients (*P* = 0.037).

Fat areas and age, cancer location, depth of cancer invasion, ulcer status, symptoms, and Helicobacter pylori infection status

Age. Because fat volumes may be associated with age, we separated the patients with early GC into two groups; a younger group (age 60 years or less) and an older group (age 61 years or more). There were no differences in TFA, VFA, or SFA values between the two groups in male patients (data not shown). However, in female patients, VFA in the older group (67.7 ± 40.1 cm²) was significantly larger than that in the younger group (34.4

± 12.5 cm²; *P* = 0.011). SFA also tended to be larger in the older group (data not shown), and the V/S ratio in the older group (0.45 ± 0.27) was significantly higher than that in the younger group (0.39 ± 0.45, *P* = 0.025). This suggests that older female patients, but not male patients, tended to have more visceral fat, and this trend is consistent with the general population data [58].

Cancer location. As previously reported in Western countries, obesity is a risk factor for cancer of the gastric cardia. Therefore, we examined the fat volumes in patients with gastric cardia and noncardia cancer. Eleven male and 2 female patients had Siewert type II cardia cancer; the remainder had noncardia cancers. In both the male and female patients, there were no significant differences in TFA, VFA, or SFA between those with cardia and noncardia cancers (Table 2).

Table 3. Fat areas and depth of cancer invasion, ulcer status, presence of symptoms, and *Helicobacter pylori* infection status

Fat areas and depth of cancer invasion			
Male	m (<i>n</i> = 105)	sm (<i>n</i> = 69)	<i>P</i> value
TFA (cm ²)	203.2 ± 89.1	194.0 ± 89.6	0.561
VFA (cm ²)	103.3 ± 53.4	98.0 ± 51.8	0.672
SFA (cm ²)	99.9 ± 44.8	96.0 ± 45.7	0.568
Female	m (<i>n</i> = 18)	sm (<i>n</i> = 18)	<i>P</i> value
TFA (cm ²)	233.7 ± 96.8	183.7 ± 84.7	0.121
VFA (cm ²)	62.8 ± 43.1	50.4 ± 29.1	0.457
SFA (cm ²)	170.9 ± 60.6	133.3 ± 64.5	0.071
Fat areas and ulcer status			
	Ulcer positive (<i>n</i> = 55)	Ulcer negative (<i>n</i> = 149)	<i>P</i> value
TFA (cm ²)	190.0 ± 82.6	205.1 ± 92.8	0.594
VFA (cm ²)	88.6 ± 48.2	95.5 ± 54.8	0.610
SFA (cm ²)	101.5 ± 50.7	109.6 ± 54.3	0.492
Fat areas and presence of symptoms			
	Symptomatic (<i>n</i> = 42)	Asymptomatic (<i>n</i> = 166)	<i>P</i> value
TFA (cm ²)	188.6 ± 76.2	205.4 ± 92.7	0.270
VFA (cm ²)	78.8 ± 41.5	97.9 ± 55.0	0.056
SFA (cm ²)	109.9 ± 54.9	107.4 ± 52.5	0.887
Fat areas and <i>H. pylori</i> infection status			
	<i>H. pylori</i> positive (<i>n</i> = 71)	<i>H. pylori</i> negative (<i>n</i> = 13)	<i>P</i> value
TFA (cm ²)	217.6 ± 91.5	188.1 ± 79.3	0.425
VFA (cm ²)	98.9 ± 54.1	98.5 ± 47.6	0.762
SFA (cm ²)	118.6 ± 53.7	89.6 ± 48.3	0.072

Data values are means ± SD

m, mucosal cancer; sm, submucosal cancer

The ulcer status of 204 of the 210 patients was confirmed; ulcer-positive, patients with active gastric ulcer (*n* = 10) or ulcer within GC lesion (*n* = 46; 1 patient had active ulcer and ulcer within GC lesion); ulcer-negative, patients with an old ulcer scar (*n* = 21) or without ulcer (*n* = 128)

Two of the 210 patients had no records about symptoms; 166 patients were asymptomatic, and 42 patients had symptoms (epigastralgia, *n* = 16; epigastric discomfort, *n* = 9; equivocal symptoms, *n* = 17)

Eighty-four patients were checked for *H. pylori* infection status

Depth of cancer invasion. We compared mucosal and submucosal cancers in relation to TFA, VFA, and SFA; these parameters were not significantly different between mucosal and submucosal cancers in either sex (Table 3).

Ulcer status. Among the 210 patients, gastric ulcer status was confirmed in 204; 128 of these patients (62.7%) did not have a gastric ulcer. However, 10 patients (4.9%) had an active gastric ulcer and 21 patients (10%) had an old ulcer scar. Moreover, ulceration was detected within the early GC lesion in 46 patients (22.5%). We found no association between ulcer status and the differentiation of early GC (*P* = 0.283) or between *H. pylori* infection

status and the differentiation of early GC (*P* = 0.643). We also found no association between ulcer status and TFA, VFA, or SFA (Table 3).

Symptoms. For 2 of the 210 patients with early GC there was no record of symptoms; 166 of the remaining 208 patients (79.8%) were asymptomatic, while 16 patients (7.6%) had epigastralgia, 9 patients (4.3%) had epigastric discomfort, and the other patients had equivocal symptoms. However, we could not detect significant differences between symptomatic and asymptomatic patients in the differentiation of early GC (*P* = 0.176), *H. pylori* infection status (*P* = 0.604), or in TFA, VFA, or SFA (Table 3).

Helicobacter pylori infection status. *Helicobacter pylori* infection is important when considering the carcinogenesis of GC. In our series, 84 patients were checked for *H. pylori* infection status, by the rapid urease test (RUT), serum *H. pylori* antibody, or microscopic examination. Among them, 71 patients (84.5%) were positive for *H. pylori*, and 13 patients (15.5%) were negative. In these patients, we analyzed the relationship of *H. pylori* infection status and other factors, and found that *H. pylori* infection did not have a significant association with the differentiation of early GC ($P = 0.610$), or with TFA, VFA, or SFA (Table 3).

Fat areas and histological differentiation

GC is histologically classified into two types based on the predominant morphological features: differentiated type (well and moderately differentiated adenocarcinomas) and undifferentiated type (poorly differentiated adenocarcinoma and signet ring cell carcinoma), and the biological features have been shown to be considerably different in these two types [59–63]. We focused on the histological type in relation to fat areas (Fig. 1). Interestingly, in male patients, VFA was significantly smaller in those with the undifferentiated type than in those with the differentiated type ($P = 0.016$). SFA also tended to be smaller in those with the undifferentiated type ($P = 0.07$). The trend was more prominent in female patients. VFA ($P = 0.004$) and SFA ($P < 0.001$) were markedly smaller in patients with undifferentiated GC than in those with differentiated histology. However, the V/S ratio, which is an index of body fat distribution,

was not different between the differentiated and undifferentiated types in either male ($P = 0.185$) or female ($P = 0.814$) patients.

Fat areas and differentiation in mucosal and submucosal cancers

Next, we compared the fat areas in patients with mucosal and submucosal cancers in those with differentiated and undifferentiated GCs separately (Fig. 2). In differentiated GCs, TFA, VFA, and SFA did not differ according to the depth of invasion in either sex. In contrast, in undifferentiated GCs (see double-asterisks in Fig. 2), SFA was significantly smaller in submucosal cancer as compared with mucosal cancer in both male ($P = 0.024$) and female ($P = 0.025$) patients. Also, in undifferentiated GCs, the difference in TFA according to depth of invasion was also statistically significant in male patients ($P = 0.039$) and marginally significant in female patients ($P = 0.055$).

From another aspect, in male patients with mucosal cancer, TFA, VFA, and SFA did not differ between cancers with differentiated and undifferentiated type histology (Fig. 2). However, when fat volumes were examined in patients with submucosal cancer (see asterisks in Fig. 2), TFA, VFA, and SFA were significantly smaller in patients with undifferentiated cancer than in those with differentiated cancer ($P = 0.007$, $P = 0.010$, and $P = 0.022$, respectively). In female patients, a similar trend was observed; in mucosal cancer also, TFA and SFA were significantly smaller in patients with undifferentiated cancer ($P = 0.039$, $P = 0.015$).

Fig. 1. Fat areas in patients with differentiated- and undifferentiated-type cancers. Male (differentiated-type cancer, $n = 151$; undifferentiated-type cancer, $n = 23$); female (differentiated-type cancer, $n = 24$; undifferentiated-type cancer, $n = 12$)
* $P < 0.05$

Fig. 2. Fat areas in patients with differentiated and undifferentiated cancers with invasion of different layers. Male (differentiated type of mucosal cancer, $n = 90$, undifferentiated type of mucosal cancer, $n = 15$; differentiated type of submucosal cancer, $n = 61$; undifferentiated type of submucosal cancer, $n = 8$); female (differentiated type of mucosal cancer, $n = 12$; undifferentiated type of mucosal cancer, $n = 6$; differentiated type of submucosal cancer, $n = 12$; undifferentiated type of submucosal cancer, $n = 6$) * $P < 0.05$ (comparison of differentiated and undifferentiated cancers in each depth of cancer invasion) ** $P < 0.05$ (comparison of mucosal and submucosal cancers in undifferentiated-type cancer) Male total fat area (TFA), $P = 0.039$; subcutaneous fat area (SFA) $P = 0.024$; female SFA, $P = 0.025$

Fat areas and histological differentiation at different ages

In the present study, patients with undifferentiated-type GC were significantly younger than patients with differentiated-type cancer (56.3 ± 12.1 and 67.6 ± 9.1 years; $P < 0.001$). We divided the patients into two groups; those aged 60 years or less and those aged 61 years or more, and reevaluated the data. As shown in Table 4, TFA, VFA, SFA were not different between differentiated and undifferentiated type cancers in the older group in male patients. However, when these fat areas were compared in the younger group in male patients, all the values were significantly smaller in the undifferentiated type. In female patients, the difference between the younger and older groups was not so evident.

Discussion

In this study, we used a slice of a CT image at the umbilicus and separately quantified the subcutaneous fat area (SFA) and visceral fat area (VFA) in patients with early gastric cancer (GC) and patients with colorectal cancer (CRC). The values were mostly consistent with those of the Japanese general population [58]. Male patients had larger VFAs, while female patients had larger SFAs. In female patients, TFA and VFA in the older group were significantly larger than those in the younger group. The same trend was reported for BMI in the general Japanese population [64]. These data indicate that adipose tissue volume and distribution are not markedly changed by the presence of early cancer lesions in the stomach.

Table 4. Fat areas in patients with differentiated and undifferentiated cancers in the two age groups

	Age 60 years or less (<i>n</i> = 49)			Age 61 years or more (<i>n</i> = 125)		
	Diff (<i>n</i> = 36)	Undiff (<i>n</i> = 13)	<i>P</i> value	Diff (<i>n</i> = 115)	Undiff (<i>n</i> = 10)	<i>P</i> value
Male						
TFA (cm ²)	216.4	138.3	*0.002	202.1	189.6	0.689
VFA (cm ²)	109.4	64.9	*0.006	103.3	95.3	0.620
SFA (cm ²)	107.0	73.4	*0.007	98.8	94.2	0.920
V/S	1.04	0.90	0.365	1.10	1.04	0.604
	Age 60 years or less (<i>n</i> = 12)			Age 61 years or more (<i>n</i> = 24)		
	Diff (<i>n</i> = 5)	Undiff (<i>n</i> = 7)	<i>P</i> value	Diff (<i>n</i> = 19)	Undiff (<i>n</i> = 5)	<i>P</i> value
Female						
TFA (cm ²)	223.5	128.0	*0.005	250.0	149.8	0.082
VFA (cm ²)	41.7	29.2	0.088	73.7	44.7	0.082
SFA (cm ²)	181.8	98.8	*0.005	176.3	105.2	*0.043
V/S	0.23	0.50	0.223	0.42	0.58	0.915

*P < 0.05

Data values are averages

Diff, differentiated-type cancer; Undiff, undifferentiated cancer

In our data, VFA and SFA, as well as BMI, were not different between the patients with GC and those with CRC. Previous reports in Western countries have shown that the BMI of patients with gastric cancer was lower than that of patients with CRC [65, 66]. The patients in those studies, however, included many with advanced cancer, whereas our patients were restricted to those with early-stage cancer. Therefore, this discrepancy is not surprising, but rather suggests that the patients with GC possess the same amount of adipose tissue as those with CRC, as long as the malignant lesions are limited to an early stage.

Demographic trends in GC differ by cancer location and histology. While there has been a marked decline in distal, differentiated-type gastric cancers, undifferentiated-type cancers of the gastric cardia are increasing, particularly in Western countries [28, 67]. Japan and Korea have the highest rates of gastric cancer in the world [68, 69], and in contrast to the increasing incidence of proximal gastric cancers in the West, distal cancers continue to predominate in Japan. However, even in Japan, the proportion of proximal gastric cancers has increased among men [70].

From these data, we raised the hypothesis that there is different association between fat volume and gastric cancers at different locations. However, in both male and female patients, TFA, VFA, and SFA, as well as BMI, did not show a significant difference between cardia and noncardia cancers. This is in contrast to previous reports in Western countries showing a strong association between obesity and cardia cancer [24, 27, 34–36]. The reason for this discrepancy is not clear. However, in the present study, the number of patients with cardia cancer was small and very obese patients were relatively rare (only 2 men out of a total of 210

patients had a BMI of more than 30). Hence, in Japan, other factors, such as salt intake or *H. pylori* infection, may have a strong contribution to the pathogenesis of gastric cardia cancer, which may mask the possible correlation with adipose tissue volume. In fact, the association between chronic *H. pylori* infection and the development of gastric cancer is well established [71–74]. In Japan, the prevalence of *H. pylori* infection is less than 20% at age 20 years, but increases to 80% in those over the age of 40 years [75]. In the present study, 84 patients were checked for *H. pylori* infection status, by the rapid urease test (RUT), serum *H. pylori* antibody, or microscopic examination. Among them, 71 patients (84.5%) were positive, and 13 patients (15.5%) were negative. We analyzed the results in relation to BMI, TFA, VFA, and SFA, and in relation to the differentiation of early GC and found that, *H. pylori* infection had no association with any of these parameters.

The most striking finding in our data is the difference in adipose tissue volumes between patients with differentiated and undifferentiated GCs. In both male and female patients, TFA, VFA, and SFA were significantly smaller in patients with undifferentiated-type cancer than in those with differentiated-type cancer, except for SFA in male patients. As compared with the general Japanese population, fat areas are considered to be reduced in patients with undifferentiated gastric cancer. These findings suggest that reduced fat volume may be mechanically related to the development of undifferentiated GC. Furthermore, the TFA, VFA and SFA values did not show a significant difference between mucosal and submucosal cancers in patients with differentiated cancer, whereas in patients with undifferentiated GC, these values tended to be lower in submucosal cancer than in mucosal cancer. With these results, we raise the

possibility that a reduced fat volume may be favorable for the submucosal invasion of undifferentiated GC. Another speculation is that undifferentiated, but not differentiated, GC may already have systemic effects inducing a reduction of subcutaneous fat volumes when invasion into the submucosal layer is present.

In our data, the difference in SFA appeared to be more prominent than that in VFA. In submucosal cancers, the differences in both SFA and VFA between differentiated and undifferentiated cancers were significant in both sexes. However, in mucosal cancers, only SFA in female patients showed a significant difference between differentiated and undifferentiated cancers. These findings suggest that SFA may be more closely related to the development and progression of undifferentiated rather than differentiated GC; this would explain the significant difference in SFA between differentiated and undifferentiated cancers in mucosal cancers only in female patients, who have, basically, larger SFAs.

In our study, in male patients, a significant difference in fat volumes between patients with differentiated and undifferentiated GCs was detected only in the younger group (60 years or less), but not in the older group (61 years or more). Thus, in male patients, the specific association between undifferentiated GC and reduced fat volume was applicable only for the younger group. This trend was not observed in female patients. The mechanisms of carcinogenesis of undifferentiated GC are markedly different according to age and sex. Many studies have suggested that GCs show considerable differences in their clinical characteristics as well as genetic background according to their histological classification [63, 76]. Our result is an additional finding on the biological difference between the two histological types of GC.

In summary, we demonstrated that the differentiated- and undifferentiated-type GCs showed different associations with adipose tissue volume. The mechanisms are not clear yet and require further investigation. However, recent studies have provided evidence that adipose tissue can produce many cytokines (adipokines), such as leptin and adiponectin, which can potentially affect the biological behavior of malignant cells [41–50]. Our data support the hypothesis that these adipose tissue-derived factors are differently associated with the carcinogenesis or progression of GC of each histological type.

References

1. Armstrong B, Doll R. Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices. *Int J Cancer* 1975;15:617–31.
2. Azevedo A, Ramos E, von Hafe P, Barros H. Upper-body adiposity and risk of myocardial infarction. *J Cardiovasc Risk* 1999;6: 321–5.
3. Donahue RP, Abbott RD, Bloom E, Reed DM, Yano K. Central obesity and coronary heart disease in men. *Lancet* 1987;I:821–4.
4. Ducimetiere P, Richard J, Cambien F. The pattern of subcutaneous fat distribution in middle-aged men and the risk of coronary heart disease: the Paris Prospective Study. *Int J Obes* 1986;10: 229–40.
5. Lapidus L, Bengtsson C, Lissner L. Distribution of adipose tissue in relation to cardiovascular and total mortality as observed during 20 years in a prospective population study of women in Gothenburg, Sweden. *Diabetes Res Clin Pract* 1990;10(Suppl 1): S185–9.
6. Larsson B, Svardsudd K, Welin L, Wilhelmsen L, Bjorntorp P, Tibblin G. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. *Br Med J (Clin Res Ed)* 1984;288:1401–4.
7. Reeder BA, Senthilselvan A, Despres JP, Angel A, Liu L, Wang H, et al. The association of cardiovascular disease risk factors with abdominal obesity in Canada. Canadian Heart Health Surveys Research Group. *CMAJ* 1997;157(Suppl 1):S39–45.
8. Hartz AJ, Rupley DC Jr, Kalkhoff RD, Rimm AA. Relationship of obesity to diabetes: influence of obesity level and body fat distribution. *Prev Med* 1983;12:351–7.
9. Despres JP, Tremblay A, Theriault G, Perusse L, Leblanc C, Bouchard C. Relationships between body fatness, adipose tissue distribution and blood pressure in men and women. *J Clin Epidemiol* 1988;41:889–97.
10. Folsom AR, Kaye SA, Prineas RJ, Potter JD, Gapstur SM, Wallace RB. Increased incidence of carcinoma of the breast associated with abdominal adiposity in postmenopausal women. *Am J Epidemiol* 1990;131:794–803.
11. Giovannucci E. Insulin and colon cancer. *Cancer Causes Control* 1995;6:164–79.
12. Hartz AJ, Rupley DC, Rimm AA. The association of girth measurements with disease in 32,856 women. *Am J Epidemiol* 1984; 119:71–80.
13. Schapira DV, Kumar NB, Lyman GH, Cavanagh D, Roberts WS, LaPolla J. Upper-body fat distribution and endometrial cancer risk. *JAMA* 1991;266:1808–11.
14. Schapira DV, Kumar NB, Lyman GH, Cox CE. Abdominal obesity and breast cancer risk. *Ann Intern Med* 1990;112:182–6.
15. Lew EA, Garfinkel L. Variations in mortality by weight among 750,000 men and women. *J Chronic Dis* 1979;32:563–76.
16. Hill HA, Austin H. Nutrition and endometrial cancer. *Cancer Causes Control* 1996;7:19–32.
17. Wolk A, Lindblad P, Adami HO. Nutrition and renal cell cancer. *Cancer Causes Control* 1996;7:5–18.
18. Hunter DJ, Willett WC. Nutrition and breast cancer. *Cancer Causes Control* 1996;7:56–68.
19. Potter JD. Nutrition and colorectal cancer. *Cancer Causes Control* 1996;7:127–46.
20. Zatonski WA, Lowenfels AB, Boyle P, Maisonneuve P, Bueno de Mesquita HB, Ghadirian P, et al. Epidemiologic aspects of gallbladder cancer: a case-control study of the SEARCH Program of the International Agency for Research on Cancer. *J Natl Cancer Inst* 1997;89:1132–8.
21. Kolonel LN. Nutrition and prostate cancer. *Cancer Causes Control* 1996;7:83–44.
22. Kolonel LN, Hankin JH, Wilkens LR, Fukunaga FH, Hinds MW. An epidemiologic study of thyroid cancer in Hawaii. *Cancer Causes Control* 1990;1:223–34.
23. Ron E, Kleinerman RA, Boice JD Jr, LiVolsi VA, Flannery JT, Fraumeni JF, Jr. A population-based case-control study of thyroid cancer. *J Natl Cancer Inst* 1987;79:1–12.

24. Chow WH, Blot WJ, Vaughan TL, Risch HA, Gammon MD, Stanford JL, et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. *J Natl Cancer Inst* 1998;90:150–5.
25. Hansson LE, Baron J, Nyren O, Bergstrom R, Wolk A, Lindgren A, et al. Early-life risk indicators of gastric cancer. A population-based case-control study in Sweden. *Int J Cancer* 1994;57:32–7.
26. Ji BT, Chow WH, Yang G, McLaughlin JK, Gao RN, Zheng W, et al. Body mass index and the risk of cancers of the gastric cardia and distal stomach in Shanghai, China. *Cancer Epidemiol Biomarkers Prev* 1997;6:481–5.
27. Lagergren J, Bergstrom R, Nyren O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. *Ann Intern Med* 1999;130:883–90.
28. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF, Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. *JAMA* 1991;265:1287–9.
29. Harrison SL, Goldacre MJ, Seagroatt V. Trends in registered incidence of oesophageal and stomach cancer in the Oxford region, 1974–88. *Eur J Cancer Prev* 1992;1:271–4.
30. Moller H. Incidence of cancer of oesophagus, cardia and stomach in Denmark. *Eur J Cancer Prev* 1992;1:159–64.
31. Powell J, McConkey CC. Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites. *Br J Cancer* 1990;62:440–3.
32. Yang PC, Davis S. Epidemiological characteristics of adenocarcinoma of the gastric cardia and distal stomach in the United States, 1973–1982. *Int J Epidemiol* 1988;17:293–7.
33. Zheng T, Mayne ST, Holford TR, Boyle P, Liu W, Chen Y, et al. The time trend and age-period-cohort effects on incidence of adenocarcinoma of the stomach in Connecticut from 1955–1989. *Cancer* 1993;72:330–40.
34. Brown LM, Swanson CA, Gridley G, Swanson GM, Schoenberg JB, Greenberg RS, et al. Adenocarcinoma of the esophagus: role of obesity and diet. *J Natl Cancer Inst* 1995;87:104–9.
35. Vaughan TL, Davis S, Kristal A, Thomas DB. Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: adenocarcinoma versus squamous cell carcinoma. *Cancer Epidemiol Biomarkers Prev* 1995;4:85–92.
36. Kabat GC, Ng SK, Wynder EL. Tobacco, alcohol intake, and diet in relation to adenocarcinoma of the esophagus and gastric cardia. *Cancer Causes Control* 1993;4:123–32.
37. Zhang J, Su XQ, Wu XJ, Liu YH, Wang H, Zong XN, et al. Effect of body mass index on adenocarcinoma of gastric cardia. *World J Gastroenterol* 2003;9:2658–61.
38. Kubo A, Corley DA. Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. *Cancer Epidemiol Biomarkers Prev* 2006;15:872–8.
39. Guerre-Millo M. Adipose tissue and adipokines: for better or worse. *Diabetes Metab* 2004;30:13–9.
40. Maeda K, Okubo K, Shimomura I, Mizuno K, Matsuzawa Y, Matsubara K. Analysis of an expression profile of genes in the human adipose tissue. *Gene* 1997;190:227–35.
41. Bub JD, Miyazaki T, Iwamoto Y. Adiponectin as a growth inhibitor in prostate cancer cells. *Biochem Biophys Res Commun* 2006;340:1158–66.
42. Cong L, Gasser J, Zhao J, Yang B, Li F, Zhao AZ. Human adiponectin inhibits cell growth and induces apoptosis in human endometrial carcinoma cells, HEC-1-A and RL95 2. *Endocr Relat Cancer* 2007;14:713–20.
43. Dieudonne MN, Bussiere M, Dos Santos E, Leneuve MC, Giudicelli Y, Pecquery R. Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cells. *Biochem Biophys Res Commun* 2006;345:271–9.
44. Dieudonne MN, Machinal-Quelin F, Serazin-Leroy V, Leneuve MC, Pecquery R, Giudicelli Y. Leptin mediates a proliferative response in human MCF7 breast cancer cells. *Biochem Biophys Res Commun* 2002;293:622–8.
45. Housa D, Housova J, Vernerova Z, Haluzik M. Adipocytokines and cancer. *Physiol Res* 2006;55:233–44.
46. Ishikawa M, Kitayama J, Yamauchi T, Kadowaki T, Maki T, Miyato H, et al. Adiponectin inhibits the growth and peritoneal metastasis of gastric cancer through its specific membrane receptors AdipoR1 and AdipoR2. *Cancer Sci* 2007;98:1120–7.
47. Kang JH, Lee YY, Yu BY, Yang BS, Cho KH, Yoon DK, et al. Adiponectin induces growth arrest and apoptosis of MDA-MB-231 breast cancer cell. *Arch Pharm Res* 2005;28:1263–9.
48. Rouet-Benzineb P, Aparicio T, Guilmeau S, Pouzet C, Descatoire V, Buyse M, et al. Leptin counteracts sodium butyrate-induced apoptosis in human colon cancer HT-29 cells via NF-kappaB signaling. *J Biol Chem* 2004;279:16495–502.
49. Schaffler A, Scholmerich J, Buechler C. Mechanisms of disease: adipokines and breast cancer –endocrine and paracrine mechanisms that connect adiposity and breast cancer. *Nat Clin Pract Endocrinol Metab* 2007;3:345–54.
50. Yin N, Wang D, Zhang H, Yi X, Sun X, Shi B, et al. Molecular mechanisms involved in the growth stimulation of breast cancer cells by leptin. *Cancer Res* 2004;64:5870–5.
51. Iannucci CV, Capoccia D, Calabria M, Leonetti F. Metabolic syndrome and adipose tissue: new clinical aspects and therapeutic targets. *Curr Pharm Des* 2007;13:2148–68.
52. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. *Endocr Rev* 2000;21:697–738.
53. Kvist H, Chowdhury B, Sjostrom L, Tylen U, Cederblad A. Adipose tissue volume determination in males by computed tomography and 40K. *Int J Obes* 1988;12:249–66.
54. Sjostrom L, Kvist H, Cederblad A, Tylen U. Determination of total adipose tissue and body fat in women by computed tomography, 40K, and tritium. *Am J Physiol* 1986;250(6 Pt 1):E736–45.
55. Tokunaga K, Matsuzawa Y, Ishikawa K, Tarui S. A novel technique for the determination of body fat by computed tomography. *Int J Obes* 1983;7:437–45.
56. Taira K, Hikita M, Kobayashi J, Bujo H, Takahashi K, Murano S, et al. Delayed post-prandial lipid metabolism in subjects with intra-abdominal visceral fat accumulation. *Eur J Clin Invest* 1999;29:301–8.
57. Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. *Br J Surg* 1998;85:1457–9.
58. Eguchi M, Tsuchihashi K, Saitoh S, Odawara Y, Hirano T, Nakata T, et al. Visceral obesity in Japanese patients with metabolic syndrome: reappraisal of diagnostic criteria by CT scan. *Hypertens Res* 2007;30:315–23.
59. Sixth annual ECP (European Organization for Cooperation in Cancer Prevention Studies) symposium. International symposium on gastric carcinogenesis. London, March 7–8, 1988. Abstracts. *Cancer Lett* 1988;39(Suppl 1):S1–45.
60. Correa P, Sasano N, Stemmermann GN, Haenszel W. Pathology of gastric carcinoma in Japanese populations: comparisons between Miyagi prefecture, Japan, and Hawaii. *J Natl Cancer Inst* 1973;51:1449–59.
61. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma: an attempt at a histoclinical classification. *Acta Pathol Microbiol Scand* 1965;64:31–49.
62. Munoz N, Correa P, Cuello C, Duque E. Histologic types of gastric carcinoma in high- and low-risk areas. *Int J Cancer* 1968;3:809–18.
63. Sugano H, Nakamura K, Kato Y. Pathological studies of human gastric cancer. *Acta Pathol Jpn* 1982;32(Suppl 2):329–47.
64. Miyawaki T. Metabolic syndrome in Japanese diagnosed with visceral fat measurement by computed tomography. *Proc Japan Acad* 2005;Ser B 81:471–9.
65. Nomura A, Heilbrun LK, Stemmermann GN. Body mass index as a predictor of cancer in men. *J Natl Cancer Inst* 1985;74:319–23.

66. Rousseau MC, Parent ME, Siemiatycki J. Comparison of self-reported height and weight by cancer type among men from Montreal, Canada. *Eur J Cancer Prev* 2005;14:431–8.
67. Brown LM, Devesa SS. Epidemiologic trends in esophageal and gastric cancer in the United States. *Surg Oncol Clin N Am* 2002;11:235–56.
68. Ahn YO, Park BJ, Yoo KY, Kim NK, Heo DS, Lee JK, et al. Incidence estimation of stomach cancer among Koreans. *J Korean Med Sci* 1991;6:7–14.
69. Yamamoto S. Stomach cancer incidence in the world. *Jpn J Clin Oncol* 2001;31:471.
70. Liu Y, Kaneko S, Sobue T. Trends in reported incidences of gastric cancer by tumour location, from 1975 to 1989 in Japan. *Int J Epidemiol* 2004;33:808–15.
71. An international association between *Helicobacter pylori* infection and gastric cancer. The EUROGAST Study Group. *Lancet* 1993;341:1359–62.
72. Forman D, Newell DG, Fullerton F, Yarnell JW, Stacey AR, Wald N, et al. Association between infection with *Helicobacter pylori* and risk of gastric cancer: evidence from a prospective investigation. *BMJ* 1991;302:1302–5.
73. Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez-Perez GI, Blaser MJ. *Helicobacter pylori* infection and gastric carcinoma among Japanese Americans in Hawaii. *N Engl J Med* 1991;325:1132–6.
74. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, et al. *Helicobacter pylori* infection and the risk of gastric carcinoma. *N Engl J Med* 1991;325:1127–31.
75. Asaka M, Kimura T, Kudo M, Takeda H, Mitani S, Miyazaki T, et al. Relationship of *Helicobacter pylori* to serum pepsinogens in an asymptomatic Japanese population. *Gastroenterology* 1992;102:760–6.
76. Tamura G. Alterations of tumor suppressor and tumor-related genes in the development and progression of gastric cancer. *World J Gastroenterol* 2006;12:192–8.